Hikma Suspends Roll-Out Of Advair Rival
Follows Amendment Filed With US FDA Over Packaging Update
Executive Summary
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.
You may also be interested in...
Vectura Agrees £958m Takeover Following Hikma Advair Launch
Weeks after partner Hikma launched its generic version of GSK’s Advair, Wiltshire-based Vectura has agreed a takeover offer by private equity Carlyle, which aims to build a market leading inhalation specialist CDMO.
Cipla Lines Up A Slate Of US Launches For FY23
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.
Big US Launch Promise For Cipla In FY23, Eyes On Peptide Filings
Cipla signals meaningful US launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid and Abraxane. Partnered peptide injectable filings also bolster pipeline opportunities.